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ABSTRACT 
Background: To analyze the academic characteristics, career trajectory, scholarly publications, and demographic background of 
the 100 most-cited authors in ophthalmic literature. 
Methods: In this observational cross-sectional study, a database containing every ophthalmology journal article from 1967 to 2018 
was built using Scopus journal article information. The 100 authors with the most citations were identified, along with a control 
group of authors with at least five publications. Information about each author, such as gender, institution, and educational 
degrees were found from online web searches. Intra- and inter-group analyses were performed to identify correlations that may 
lead to having a high level of impact in ophthalmology literature. 
Results: Of the 100 most-cited ophthalmologists, 56 practice in the United States (US) and only 12 are female. In an odds ratio 
(OR) analysis, highly-cited researchers more often lived in the US (OR, 2.97; P < 0.001), were male (OR, 2.4; P = 0.02), and graduated 
from an elite medical school (OR, 3.89; P = 0.02) and/or residency (OR, 3.67; P = 0.02), but were not from an undergraduate 
institution (P = 0.75). There was no difference in citation numbers between different ophthalmology subspecialties (P = 0.22) or 
advanced degrees (PhD, MPH in addition to MD). Women among the top-100-cited authors were more likely to author high impact 
journal articles (P < 0.05). 
Conclusions: Among highly-cited ophthalmologists, practicing in the US and attending a top medical school or residency program 
may provide training for a successful research career in ophthalmology. Additionally, top female ophthalmologists participate in 
more influential research. 
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INTRODUCTION 
The impact of a career in ophthalmic research is based on 
a series of decisions. These include selecting a medical 
school and residency program, choosing between 
academic and private practice, whether to pursue 
fellowship training and/or additional advanced degrees 
such as a Master of Public Health (MPH), Master of 
Business Administration (MBA), or Doctor of Philosophy 
(PhD). These options can be instrumental in facilitating a 
fruitful academic career [1-4]. Previous studies have 
described the characteristics of American ophthalmology 
residency program directors [1], department chairs [2], 
and clinician-scientists receiving National Institute of 
Health (NIH) grants [3]. Gershoni et al. investigated the 
impact of subspecialty choice on research productivity, 
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ABSTRACT
Background: Glauc ma is a pro ressive, irreversible optic neuropathy that results in serious vision loss 
and bli dness. This review aimed to summarize key concepts of primary open angle glaucoma (POAG) 
pharmaceu ical tr atment trials over the last deca e. 
M th s: We searched PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to August 31, 
2020, using the key words “POAG” and “Ocular topical therapeutics”. This search yielded 77 and 120 papers, 
re p ctiv ly. 
Results: Thirty-three records were compatible with our inclusion criteria. Pharmaceutical treatment is 
a common intervention in POAG for lowering IOP. Prostaglandin (PG) analogues are most commonly 
recommended as initial me ical th apy, which are administrated either as a monotherapy or in combination 
w th oth r IOP-l w ring class s f med cations. Alternative therapies, such as β-blockers, α-2 adrenergic 
re epto  agonists, and topical carbonic anhydrase inhibitors, have been used in combination or as a 
monotherapy. Rho-kinase inhibitors, such as netarsudil 0.02%, AR-13324 0.02%, and ripasudil are new IOP-
l wering medications. Despite IOP reduction, there is a significant number of patients with POAG that may 
experience disease progression, and the risk of blindnes  over the long term is considerable. 
Conclusions: Clinical trials have indicated that pharmaceutical treatment of POAG is effective and safe. 
In addition, th  new novel Rho-kinase inhibitors have shown significant IOP reduction. The new fixed 
combinations have also yielded ig ficant reductions in IOP. POAG is a cause of irreversible vision loss, if 
not diagnosed and treated early. The conditi  is likely to progress in a significant number of patients, with a 
considerable risk of blindness in the long-term.
KEY WORDS  
primary open angle glaucoma, POAG, intervention study, randomized clinical trials, RCTs, drug therapies, 
pharmaceutical treatment, medical therapy, prostaglandin analogues, beta adrenergic blockers, α-2 adrenergic 
receptor agonist, carbonic anhydrase inhibitor, Rho-kinase inhibitor
Copyright © Author(s). This is an open-access article distributed under the terms of the Creative Commons 
Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) 
which permits copy and redistribute the material just in noncommercial usages, provided the original work is 
properly cited. 
INTRODUCTION
Glaucoma is the second leading cause of blindness worldwide. Primary open-angle glaucoma (OAG) is the 
most prevalent type of glaucoma in almost all countries. Primary OAG is a progressive optic neuropathy that 
causes retinal ganglion cell axon loss and visual field deterioration. Usually, glaucoma progresses gradually 
over the course of years, and the progression of vision loss can be delayed with treatment [1, 2]. A longitudinal 
cohort study found that the prevalence rate of primary OAG in patients aged ≥ 50 years was 2.79% [3]. In a 
randomized cohort study, the definite glaucoma prevalence was 1.1% in patients aged 45‒49 years at the time 
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of clinical examination [4]. 
Elevated intraocular pressure (IOP) [5, 6] and older age [7-9] are the most important risk factors for the 
development and progression of primary OAG, of which only IOP is a modifiable factor [10]. Other risk 
factors include a family history of glaucoma [8, 11, 12], African American ancestry [13, 14], systemic disease 
[15], thinner corneas [16], myopia [17], and steroid use [18]. Since IOP is the only modifiable risk factor, 
management of primary OAG has focused on decreasing IOP, which can delay disease progression, decrease 
the visual field (VF) loss rate, and protect against visual function loss and vision loss [19]. 
This review aimed to include current evidence on the primary OAG pharmaceutical treatment. The key 
concepts of the primary OAG trials performed over the last decade were identified and summarized.
METHODS 
A literature search was conducted using PubMed/MEDLINE and clinicaltrials.gov from January 1, 2010, to 
August 31, 2020, using the keywords “POAG” and “ocular topical therapeutics.” The keyword “completed” 
was added to the keyword list for the clinicaltrials.gov search. No language limitation was applied. The search 
of these databases identified 77 and 120 potentially relevant reports, respectively. The full-text review of these 
papers yielded 33 papers considered to be compatible with our inclusion criteria.
RESULTS
Table 1 summarizes the characteristics and key findings of the 33 included studies, which were clinical trials 
and prospective studies. The most frequently used medications for IOP control were prostaglandin (PG) 
analogues, β-blockers, carbonic anhydrase inhibitors (CAIs), and α-2 adrenergic agonists. PG analogues 
were the most widely used treatment. Table 2 summarizes the mechanisms of action of each IOP-lowering 
medication. 
PG analogues were prescribed either alone or in combination with β-blockers, CAIs, and α-2 adrenergic 
agonists. In newly diagnosed, treatment-naive OAG or ocular hypertension (OHT) patients, topical PG 
analogues, including bimatoprost, latanoprost, and travoprost, were effective at lowering IOP. Although 
bimatoprost was initially the most effective, no significant difference in efficacy among the different PG 
analogues was found after 6 months [20]. A prospective, multicenter observational cohort study of 1221 
normal, suspected glaucoma, and definite glaucoma subjects revealed the impact of IOP reduction after 
administration of latanoprost 0.005% in reducing VF deterioration in newly diagnosed OAG [21]. In another 
randomized controlled trial (RCT) on newly diagnosed, treatment-naive OAG or OHT patients, patients who 
did not respond to 1 month of latanoprost were switched to another topical PG (bimatoprost or travoprost) 
which had no additive benefit [22]. A significant IOP-lowering effect of once-daily travoprost was reported 
in a clinical trial of patients with OAG or OHT [23]. Once-daily administration of benzalkonium chloride 
(BAK)-preserved travoprost 0.004% was an effective IOP-lowering treatment in patients with newly diagnosed 
primary OAG [24]. Once-daily administration of bimatoprost 0.03% or travoprost 0.004% achieved effective 
IOP reduction in patients with primary OAG or OHT. However, the effect of bimatoprost on the mean IOP 
was more but not significant [25]. Preservative-free (PF) latanoprost had better tolerability and a comparable 
IOP-lowering effect as compared to BAK–latanoprost in patients with glaucoma or OHT [26].
In addition to the above trials on PG analogues per se, a few other studies compared their efficacy against 
different classes of IOP-lowering eye drops. Among adult subjects with unilateral or bilateral OAG or OHT, 
latanoprostene bunod (LBN) 0.024% every evening had a greater IOP-lowering effect than timolol 0.5% 
twice daily during the daytime, over 3 months of treatment. This study verified the efficacy and safety of LBN 
[27]. LBN administered at 8 PM had a greater IOP reduction and ocular perfusion pressure increase during 
the night hours than timolol 0.5% twice daily in patients with OHT or early primary OAG [28]. The mean 
24-hour IOP-lowering effect of bimatoprost 0.01% and timolol 0.5% were comparable, but bimatoprost 0.01% 
was more effective than timolol 0.5% during the nocturnal period [29]. 
The efficacy and safety of either preserved or PF fixed combination (FC) of PG analogues with timolol 
were also investigated. The efficacy of a PF latanoprost/timolol FC was equivalent to that of BAK-preserved 
latanoprost/timolol FC. This treatment was well-tolerated in patients with OAG or OHT who were previously 
treated with the preserved formulation, and the overall safety profile was similar [30]. The IOP-lowering 
effect of a PF tafluprost 0.0015%/timolol 0.5% FC was greater than that of both tafluprost (0.0015%) and 
timolol (0.5%) monotherapies [31]. The once-daily administration of a FC of latanoprost/timolol further 
reduced IOP compared with twice daily 0.50% timolol monotherapy in patients with primary OAG [32]. 
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The IOP-lowering effect of a PF tafluprost/timolol FC was comparable to that of a preserved latanoprost/
timolol FC. A tafluprost/timolol FC improved superficial punctate keratopathy scores [33]. Moreover, a PF 
tafluprost/timolol FC reduced IOP in primary OAG and OHT patients [34]. The IOP-lowering effect of a 
FC of bimatoprost/timolol in Chinese patients with OAG or OHT was comparable with concurrent dosing 
with the single components [35]. Once-daily administration of a FC of bimatoprost 0.03%/timolol maleate 
0.5% had greater IOP-lowering efficacy than the triple combination of dorzolamide 2%, brimonidine 0.2%, 
and timolol maleate 0.5%, although both treatment types were well-tolerated [36].
An additive IOP-lowering effect of topical brimonidine added to topical PG was seen in patients with 
primary OAG or OHT, but this effect was less than that of topical timolol as monotherapy [37]. Patients 
with glaucoma with symptoms or signs of ocular surface disease, who were treated with BAK-preserved 
latanoprost, were switched to PF tafluprost therapy and a triple PF treatment (tafluprost and dorzolamide/
timolol FC). These patients had significantly lower mean, peak, and fluctuation of 24-hour IOP following 
treatment with PF-tafluprost, and enhanced ocular surface parameters and tolerability. On the other hand, the 
triple PF treatment yielded a more significant 24-hour IOP control than latanoprost baseline therapy [38]. 
The IOP-lowering outcome of PF timolol 0.1% gel in treatment-naive patients with primary OAG or OHT 
was effective. Furthermore, this treatment reduced ocular signs and symptoms in patients who were intolerant 
to preserved eye drops [39]. The IOP-lowering effect of both PF and preserved brimonidine tartrate in patients 
with OAG or OHT was comparable. Formulations of brimonidine tartrate showed no significant differences 
in pain, stinging, and blurred vision after instillation. However, at the first instillation, the PF formulation 
produced a significantly greater burning sensation than the preserved formulation [40].
No significant differences were found in IOP, retrobulbar blood flow velocities, and ocular perfusion pressure 
between brimonidine/timolol and dorzolamide/timolol FCs after 1 month of treatment in patients with 
primary OAG [41]. A topical FC of brinzolamide 1% and brimonidine 0.2% was safe and effective in lowering 
IOP in a 3-month period in patients with OHT or OAG, and reduced IOP significantly more than either 
brinzolamide 1% or brimonidine 0.2% monotherapy [42]. Azarga (a FC of brinzolamide 1%/timolol 0.5% 
suspension) had better tolerability than Cosopt (a FC of dorzolamide 2%/timolol 0.5% solution) in patients 
with primary OAG [43]. Administration of topical CAIs either as monotherapy or in combination with other 
IOP-lowering medications resulted in a significantly greater difference in IOP measured by dynamic contour 
tonometry (DCT) and Goldmann applanation tonometry (GAT). The diagnosis type (OAG or OHT) and 
the number of IOP-lowering medications had no significant influence on the difference in IOP as measured 
using the two instruments [13]. Dorzolamide/timolol and brinzolamide/timolol FCs effectively decreased 
IOP, which was a lower target IOP with dorzolamide/timolol than with brinzolamide/timolol, in patients 
with primary OAG or normal tension glaucoma [44].
Rho-kinase inhibitors, such as netarsudil 0.02% (which has been used since 2018), AR-13324 0.02%, and 
ripasudil were recently shown to have IOP-lowering effects. Netarsudil 0.02% once-daily was non-inferior to 
timolol. A clinically and statistically significant IOP-lowering effect of netarsudil 0.02% once-daily has been 
reported [45]. AR-13324 0.02% (a small molecule inhibitor of Rho-kinase) was not as efficient as latanoprost 
in patients with OAG or OHT, with unmedicated IOPs of 22‒35 mmHg [46]. Ripasudil reduced IOP for at 
least 7 h following instillation in patients with primary OAG or OHT [47]. Topical administration of ripasudil 
0.4% alone or in combination with PG analogues or β-blockers over 1 year had sustained IOP-lowering effects 
and acceptable safety profiles in patients with OAG (primary OAG and exfoliation glaucoma) or OHT [48]. 
A once-daily FC of netarsudil/latanoprost had a significant IOP-lowering effect, which was superior to that 
of netarsudil and latanoprost monotherapy, in patients with OAG or OHT [49]. Once-daily netarsudil had 
a comparable IOP-lowering effect as compared to twice-daily timolol, with similar frequencies of adverse 
effects and a similar tolerability profile in adults with bilateral OAG or OHT [50]. Finally, MGV354 0.1% 
(soluble guanylate cyclase) showed no statistically significant IOP-lowering effect as compared to vehicle-
treated patients in  subjects with OHT or glaucoma [51]. 
DISCUSSION
The pathophysiology of primary OAG pertaining to retinal ganglion cell loss is linked to the IOP level. The IOP is 
dependent on the equilibrium between the aqueous humor of the ciliary body and its drainage by two individual 
pathways: the trabecular meshwork (conventional) and the uveoscleral (non-conventional) outflow pathways. 
Primary OAG patients have increased resistance to aqueous outflow through the trabecular meshwork [62].
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Table 1. Characteristics of included studies in this review and summary of their main concepts
First author Study design Main Findings




Bimatoprost, latanoprost, and travoprost had effective IOP-lowering outcomes, but bimatoprost was the 
most effective in the initial phase. However, after 6 months of treatment, the difference in the efficacy of 
the three topical PG analogues was not statistically significant.




A significant IOP-lowering effect of once-daily travoprost in patients with OAG or OHT was found.




Once-daily administration of bimatoprost 0.03% or travoprost 0.004% achieved effective IOP reduction 
in patients with primary OAG or OHT. However, bimatoprost provided a greater, although non-signifi-
cant mean IOP-lowering effect as compared to baseline.
Pacella et al., 2010 
[32]
Prospective study Once-daily administration of a FC of latanoprost/timolol could further reduce IOP than twice daily 
0.50% timolol, in patients with primary OAG.
Araie et al., 2012 
[37]
Phase III clinical trial An additive IOP-lowering effect of topical brimonidine in addition to topical PG in patients with primary 
OAG or OHT was found; this treatment was less effective than topical timolol as monotherapy.




Better tolerability of Azarga (a FC of brinzolamide 1%/timolol 0.5% suspension) than Cosopt (a FC of 
dorzolamide 2%/timolol 0.5% solution) was seen in patients with primary OAG.




The differences in IOP, retrobulbar blood flow velocities, and ocular perfusion pressure between brimo-
nidine/timolol and dorzolamide/timolol were not significant after 1-month treatment in patients with 
primary OAG.
Katz et al., 2013 
[42]
Phase III, double-masked, 
parallel-group, multicenter 
RCT
Topical administration of a FC of brinzolamide 1%/brimonidine 0.2% was safe and effective in IOP 
reduction over 3 months in patients with OHT or OAG, with a significant greater IOP-reduction than 
with brinzolamide 1% or brimonidine 0.2% monotherapy.






IOP-lowering with latanoprost 0.005% reduced visual field deterioration of newly diagnosed OAG. The 
early stage of the glaucoma and relatively low baseline IOP indicated markedly sensitive case findings in 
patients with previously untreated OAG.
Tomic et al., 2013 
[24]
Prospective study Once-daily administration of BAK-preserved travoprost 0.004% was an effective IOP-lowering treatment 
in patients with newly diagnosed primary OAG.
Tzamalis et al., 
2013 [13]
A randomized cross-sectional 
study
Significant greater difference in IOP measured by DCT and GAT was detected after treatment with 
topical CAIs, either as monotherapy or in combination with other IOP-lowering medications. Patient 
diagnosis (OAG or OHT) and the number of IOP-lowering medications had no significant influence on 
this difference.




AR-13324 0.02% (a small molecule inhibitor of Rho-kinase) had a less marked IOP-lowering effect than 
latanoprost in patients with OAG or OHT, with unmedicated IOPs of 22‒35 mmHg.
Garcia-Lopez et 
al., 2014 [36]
Phase IV, 6-month, investi-
gator-masked, prospective, 
crossover multicenter RCT
Once-daily bimatoprost/timolol could have a greater IOP-lowering efficacy than the triple FC of dorzol-
amide 2%, brimonidine 0.2%, and timolol maleate 0.5% (dorz/brim/tim; Krytantek). Both treatment 
types were well-tolerated.




The IOP-lowering effect of a FC of bimatoprost 0.03%/timolol maleate 0.5% was seen in Chinese 
patients with OAG or OHT and was comparable with concurrent dosing with the single components.
Pfeiffer et al., 2014 
[31]
Phase III, stratified, 
double-masked, multicenter 
RCT
The IOP-lowering effect of a PF tafluprost 0.0015%/timolol 0.5% FC was better than that of tafluprost 
0.0015% or timolol 0.5% monotherapy.





Ripasudil reduced IOP within 7 hours after instillation in patients with primary OAG or OHT.




The mean 24-hour IOP-lowering effect of bimatoprost 0.01% and timolol 0.5% are comparable, but 
bimatoprost 0.01% was more effective than timolol 0.5% during the night hours. 
Galose et al., 2016 
[44]
Prospective, controlled, RCT Dorzolamide/timolol and brinzolamide/timolol provided effective IOP reduction. The reduction was 
greater and lower target pressures were achieved with dorzolamide/timolol than with brinzolamide/
timolol in patients with primary OAG or normal tension glaucoma.




LBN eye drop instillation at 8 PM yielded a greater IOP reduction and ocular perfusion pressure increase 
than timolol 0.5% twice daily during the night hours in patients with OHT or early primary OAG.




Topical administration of ripasudil 0.4% alone or paired with PG analogues or β-blockers over 1 year had 
a sustained IOP-lowering effect and an acceptable safety profile in patients with OAG (primary OAG 
and exfoliation glaucoma) or OHT.
Weinreb et al., 
2016 [28]
Phase III, double-masked, 
parallel-group multicenter 
RCT
LBN eye drop instillation every evening yielded a greater IOP-lowering effect than timolol 0.5% twice 
daily, in the daytime, in adults with OAG or OHT over a 3-month period of treatment. Efficacy and 
safety of LBN was also reported.





Patients with glaucoma and concurrent symptoms or signs of ocular surface disease on BAK-preserved 
latanoprost were switched to PF tafluprost therapy or a triple PF regimen (tafluprost and dorzolamide/
timolol FC). A significantly lower mean, peak, and fluctuation of 24-hour IOP was seen after treatment 
with PF-tafluprost, along with enhancement of ocular surface parameters and tolerability. The triple PF 
medication produced a significantly greater 24-hour IOP control than seen with the latanoprost baseline 
treatment.
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Lazreg et al., 2018 
[39]
Phase IV, open-label, 
non-controlled, multicenter 
RCT
PF timolol 0.1% gel was effective in lowering IOP in treatment-naive patients with primary OAG or 
OHT. Furthermore, it reduced ocular signs and symptoms in patients who were intolerant to preserved 
eye drops.
Serle et al., 2018 
[45]
Two large double-masked, 
noninferiority RCTs 
Once-daily netarsudil 0.02% was non-inferior to timolol. A clinically and statistically significant IOP-low-
ering effect of once-daily netarsudil 0.02% was reported.
Stacy et al., 2018 
[51]
Phase I and II, dou-
ble-masked, randomized, and 
vehicle-controlled, study
MGV354 0.1% (soluble guanylate cyclase) had no significant IOP-lowering effect as compared to vehicle 
in patients with OHT or glaucoma.
Suzuki et al., 2019 
[33]
Prospective, open-label RCT The IOP-lowering effect of a preserved tafluprost/timolol FC was comparable with that of a preserved 
latanoprost/timolol FC. Tafluprost/timolol revealed an improvement in superficial punctate keratopathy 
scores.
Aptel et al., 2019 
[30]
Phase II, parallel-group, 
investigator-masked RCT
A PF latanoprost/timolol FC showed equivalent efficacy as compared with a BAK-preserved latano-
prost/timolol FC. It was well-tolerated in patients with OAG or OHT who were previously treated with 
the preserved formulation, and the overall safety profile was similar.
Blondeau et al., 
2019 [22]
A prospective randomized 
switch design study
Switching latanoprost to another topical PG (bimatoprost or travoprost) had no additive benefit for 





PF latanoprost had better tolerability and a comparable IOP-lowering effect as compared to BAK–latano-
prost in patients with glaucoma or OHT.
Asrani et al., 2020 
[49]




A once-daily FC of netarsudil/latanoprost had a significant IOP-lowering effect, which was superior to 
netarsudil and latanoprost monotherapy in patients with OAG or OHT.
Duru et al., 2020 
[40]
RCT The IOP-lowering effect of both PF and preserved brimonidine in patients with OAG or OHT was 
comparable.




A PF tafluprost/timolol FC reduced IOP in primary OAG and OHT. 
Singh et al., 2020 
[50]
Pooled data of the ROCK-
ET-1 to -4 randomized, phase 
III trials
Once-daily netarsudil had a comparable IOP-lowering effect against twice-daily timolol, with similar 
frequencies of adverse effects and a similar tolerability profile in adults with bilateral OAG or OHT.
Abbreviations: BAK, benzalkonium chloride; CAIs, Carbonic Anhydrase Inhibitors; DCT, dynamic contour tonometry; FC, fixed 
combination; GAT, Goldmann applanation tonometry; IOP, Intraocular pressure; LBN, latanoprostene bunod ophthalmic solution 0.024; 
mmHg, millimeters of mercury; OAG, open angle glaucoma; OHT, ocular hypertension; PG, prostaglandins; PM, afternoon; PF, preservative-
free; ROCKET-1, Rho Kinase Elevated IOP Treatment Trial 1; RCT, Randomized Controlled Trial.
Table 2. Summary of mechanism of action of intraocular pressure (IOP)-lowering medications 
Drug Class Mechanism of action 
ROCK inhibitor* and norepineph-
rine transporter inhibitor
The netarsudil IOP-lowering effect was accomplished via three effects on aqueous humor dynam-
ics, including a trabecular-outflow facility increase, and aqueous humor production decrease, as 
well as an episcleral venous pressure decrease [52, 53].
PG analogues Increases uveoscleral outflow. One plausible mechanism may involve induction of metallopro-
teinases in the ciliary body, and breakdown of the extracellular matrix, with subsequent reduction 
in outflow resistance through the uveoscleral pathway (traditional PG analogues: bimatoprost, 
latanoprost, and travoprost) [28, 54-57]. 
Beta-adrenergic agonists Aqueous humor production is apparently activated by a β receptor-mediated cyclic adenosine 
monophosphate (AMP) /protein kinase A (PKA) pathway. β blockers blunt adrenergic activa-
tion of this pathway. An additional hypothesis is that ocular blood flow is reduced by β blockers, 
which subsequently leads to reduction in the ultrafiltration that controls aqueous production [58, 
59].
Alpha-adrenergic agonists Reduce IOP by reducing aqueous humor production, and by enhancing both conventional and 
uveoscleral outflow [60].
Carbonic anhydrase Inhibitors Reduce bicarbonate ion formation and fluid transport, and consequently, the IOP [30].
Note: * ROCK inhibitor and norepinephrine transporter inhibitor [61], example netarsudil (AR-13324). 
Currently, IOP is the single modifiable risk factor in the management of glaucoma. The goal of therapy is to 
prevent or delay glaucoma progression by reducing IOP, regardless of the initial IOP level [9, 63]. Pharmaceutical 
treatment is a common intervention in primary OAG for IOP reduction. The first line of therapy for primary 
OAG in published guidelines is topical eye drops [64, 65]. Therefore, we concentrated only on pharmaceutical 
treatment rather than surgical procedures or laser intervention.
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PG analogues 
PG analogues are more widely used to reduce IOP than other classes [1, 64, 65]. Compared to placebo, 
bimatoprost, latanoprost, and travoprost are among the most efficacious drugs for decreasing IOP in 3 months, 
although the variations within the class were small and probably not clinically significant [19]. PG analogues 
have increasingly replaced β-adrenergic receptor antagonists as first-line medical therapy because of their once-
daily dosing, low occurrence of systemic side effects, and potent IOP-lowering effect. While PG analogues are 
the most commonly recommended first-line medications, both PG analogues and β-blockers are considered 
as first-line medications to lower IOP [1, 64, 65]. Examples of PG analogues (PGF2α analogues) available as 
eye drops are latanoprost, travoprost, bimatoprost, tafluprost, and unoprostone. Unoprostone and tafluprost are 
available for prescription in Japan. Generic latanoprost has been demonstrated to be no less, and probably more 
effective than its branded counterparts, in avoiding the need for additional treatment modalities [66]. Patients 
who were non-responsive to latanoprost did not benefit from switching to other topical PG analogues [22].
PF latanoprost has at least the same IOP-reducing effectiveness as BAK-preserved latanoprost, with a higher 
tolerability profile. This could result in better treatment control and improved quality of life [26]. Once-daily 
administration of travoprost reduced IOP [23]. BAK-preserved travoprost 0.004% disrupted the tear film 
stability in the long-term, despite having a significant IOP-lowering effect [24]. Bimatoprost, latanoprost, and 
travoprost were effective at lowering IOP, with comparable long-term results [20].
Beta-adrenergic antagonists 
Nonselective β-blockers that bind to both β1 and β2 receptors include timolol, levobunolol, metipranolol, and 
carteolol [58]. The β1-selective antagonist betaxolol is available for ophthalmic use, but is less effective. PF 
timolol 0.1% gel effectively reduced IOP in treatment-naive patients [39].
Alpha-adrenergic agonists 
If the use of PG analogues or β-receptor antagonists is contraindicated, other agents, such as α-2 adrenergic 
receptor agonists or topical CAIs, can be administered as first-line treatment. Examples of α-adrenergic agonists 
are brimonidine tartrate ophthalmic solution 0.1% or 0.15 % (Alphagan-P), brimonidine tartrate ophthalmic 
solution 0.2%, and apraclonidine HCL 0.5% or 1 % (Idopidine). PF brimonidine tartrate and preserved 
brimonidine % 0.15 preparations decreased IOP at a similar rate [40].
Carbonic anhydrase inhibitors
Examples of CAIs are dorzolamide and brinzolamide. A FC of PF latanoprost/timolol T2347 showed similar 
efficacy to that of BAK-preserved latanoprost/timolol [30]. In comparison, a triple PF tafluprost with PF 
dorzolamide/timolol FC resulted in a significant improvement in 24-hour IOP control as compared to the 
latanoprost baseline treatment [38]. Administration of CAIs either as monotherapy or in combination with 
other IOP-lowering medications resulted in a statistically significant difference in IOP measured by DCT and 
GAT [13].
Rho-kinase inhibitors 
Treatment with netarsudil 0.02% ophthalmic solution (a Rho-kinase inhibitor) was effective and well-tolerated 
once-daily in patients with OHT and OAG [45, 50]. The administration of 0.4% ripasudil, another Rho-kinase 
inhibitor, for 52 weeks resulted in a decrease in IOP and an acceptable safety profile in patients with OAG or 
OHT, whether treated as monotherapy or additive therapy [48].
Fixed combination products
All four classes of pharmaceuticals can be applied as additive second- or third-line treatments. The β-receptor 
antagonist timolol has been paired with CAIs, such as dorzolamide in a single medication. In addition, timolol 
was combined with the α-2 adrenergic agonist brimonidine. Furthermore, a brinzolamide/brimonidine 
combination has recently been introduced, and a latanoprost/timolol combination is also widely available. 
These combinations minimize the number of drops required and enhance patient compliance. A once-daily FC 
of netarsudil/latanoprost had a significant IOP-lowering effect, which was superior to that of netarsudil and 
latanoprost monotherapy in patients with OAG or OHT [49]. The PF tafluprost/timolol FC decreased IOP 
when administered in combination, as compared to as monotherapy [31, 33, 35]. In addition, another study 
showed that PF tafluprost/timolol yielded the greatest decrease in IOP at week 4, and that this was sustained 
throughout the 6-month study duration [34]. The IOP-lowering effect of bimatoprost and timolol was comparable 
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at 24 hours [29]. Once-daily bimatoprost/timolol may have better IOP-lowering efficacy than dorzolamide/
bimatoprost/timolol [36]. Topical brimonidine has an additive IOP-lowering effect when added to topical PG 
analogues, but its IOP-lowering effect was lower than that of topical timolol monotherapy [37]. Brinzolamide 
1% plus timolol 0.5% suspension is more tolerable than dorzolamide 2% plus timolol 0.5% [43]. A once-daily 
latanoprost/timolol combination reduced IOP and retained IOP control over the 24-month observation period 
[32]. 
LBN 0.024% demonstrated greater IOP-lowering effects than timolol 0.5% twice daily, during daytime, over 
3 months of treatment [28]. LBN (administered at 8 PM) induced more IOP reduction and increased ocular 
perfusion pressure during the nocturnal period more than timolol (administered at 8 AM and 8 PM) [28]. After 
1 month of treatment, brimonidine/timolol and dorzolamide/timolol resulted in well-controlled IOP in OAG 
patients, with a significant difference in the IOP [41]. The IOP-lowering effect of MGV354 0.1%, which is a 
soluble guanylate cyclase, was not significant [51]. 
In primary OAG patients, an FC of brinzolamide 1%/brimonidine 0.2% was a safe and effective IOP-
lowering therapy and provided a significantly greater IOP-lowering activity as compared to either brinzolamide 
or brimonidine monotherapy [42]. Both FCs of brinzolamide/timolol and of dorzolamide/timolol provided 
effective IOP reduction, although patients treated with dorzolamide/timolol were more likely to achieve lower 
target pressures than those treated with brinzolamide/timolol [44]. Both bimatoprost and travoprost effectively 
decreased IOP, but bimatoprost provided a larger, although statistically non-significant, reduction in mean IOP 
from baseline [25]. In treatment-naive patients with IOPs of 22‒35 mmHg, netarsudil (AR-13324) 0.02%, was 
not as effective as latanoprost [46]. 
There is a very strong correlation between the baseline, untreated IOP level and the amount of IOP reduction, 
and there appears to be a lower threshold of about 15 mmHg where treatment did not yield any IOP reduction. 
The importance of the disclosure of the baseline IOP level in addition to the IOP-lowering effect of drugs has 
been acknowledged [63]. 
A strength of this review is that it focused on primary OAG pharmaceutical interventions. In addition, 
the mechanism of action of each drug class was summarized, and new interventions, such as netarsudil and 
ripasudil, which are inhibitors of Rho-kinase, were discussed. Additionally, it provided an update on the latest 
FC interventions that have been studied in clinical trials. The limitation of this review is that it did not include a 
discussion of any laser or surgical procedures. Future studies focusing on both the safety and efficacy of available 
drug classes, besides the effects of their FC eye drops on compliance and adherence of patients with glaucoma, 
could provide a more comprehensive and practical overview of the outcomes of pharmaceutical treatment of 
glaucoma. 
CONCLUSIONS
This review highlighted that new medications yield a significant decrease in IOP in patients with primary OAG. 
Primary OAG is a cause of irreversible vision loss. If it is not diagnosed and treated early, the condition is likely 
to progress in many patients, and the long-term risk of blindness is considerable. This review highlights that the 
novel Rho-kinase inhibitors have shown significant IOP reduction and that new FCs markedly reduce IOP. 
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